|

MK-2010 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since September 2026

Also known as: LM-299

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC2

Indications

  • Cancer2
  • Ovarian Cancer Recurrent1
  • Malignant Neoplasm1
  • Advanced Solid Tumors1

New Haven, Connecticut1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

Phase 1/2

San Antonio, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.